Opinion|Videos|April 29, 2024
Comparing BTK Inhibitors for Optimal CLL Treatment
Nitin Jain, MD, discusses the increasing use of various Bruton's tyrosine kinase inhibitors as front-line treatment options for patients with chronic lymphocytic leukemia.
Advertisement
Advertisement
Related to this article
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.
Amir T. Fathi, MD, discusses how azacitidine/venetoclax’s lower toxicity and hospitalization burden should factor into treatment decisions.
Azacitidine/venetoclax improving EFS over chemotherapy in fit patients with AML is an “important outcome,” according to Amir T. Fathi, MD.
Poster presentations at SOHO 2026 may inform practice across acute lymphoblastic leukemia, acute myeloid leukemia, and chronic lymphocytic leukemia.
Combination approvals for revumenib and ziftomenib in relapsed/refractory acute myeloid leukemia may arrive before frontline approvals, according to Eunice Wang, MD.
Data from the phase 2 PARADIGM trial may support the use of less toxic, more gentle therapies for patients with acute myeloid leukemia.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
2
Screening for CHIP Mutations to Guide CAR T Cell Candidacy in Lymphoma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
5